TNFRSF9 and neoplasm: Tissue-specific recognition was quantified as the frequency of CD137+ CD8+ PILs, measured by flow cytometry (Supplementary Figure S3c), given that CD137 is essential for identifying tumor-reactive lymphocytes [22].